PPARdelta is a ligand-dependent negative regulator of vitamin D3-induced monocyte differentiation.
A number of reports indicate that peroxisome proliferator-activated receptor (PPAR) delta is involved in the molecular control of monocyte-macrophage differentiation. In this regard, the recent demonstration that PPARdelta is a primary response gene of 1alpha,25-dihydroxyvitamin D3 (VD), i.e. a powerful inducer of such process, allowed us to hypothesize the existence of a cross talk between PPARdelta and VD receptor pathways. To address this issue, we analyzed the effects promoted by stimulation with PPARdelta ligands and by overexpression of this nuclear receptor in monoblastic cell lines undergoing exposure to VD. The results obtained evidenced that, although promoting a weak differentiation effect by themselves, PPARdelta ligands efficiently co-operated with VD treatment. In spite of this, PPARdelta overexpression exerted a remarkable inhibitory effect on monocyte-macrophage differentiation induced by VD that was, at least partly, reverted by stimulation with a highly specific PPARdelta ligand. These data indicate that, although acting through a ligand-dependent modality, PPARdelta is a negative regulator of VD-mediated monocyte differentiation, allowing us to hypothesize a role of the investigated nuclear receptor in the differentiation block of M5 type (monoblastic) acute myeloid leukemias (AMLs). Bioinformatic analysis of a microarray database, containing the expression profiles of 285 AML cases, further supported this hypothesis demonstrating the existence of a subset of M5 type (monoblastic) AMLs that overexpress PPARdelta gene.
Lymboussaki
Athina
A
Department of Biomedical Sciences, University of Modena and Reggio Emilia, 41100 Modena, Italy.
Gemelli
Claudia
C
Testa
Anna
A
Facchini
Giulia
G
Ferrari
Francesco
F
Mavilio
Fulvio
F
Grande
Alexis
A
D018952:Antigens, CD34 / Q000378:metabolism; D000943:Antigens, Differentiation / Q000378:metabolism; D016718:Arachidonic Acid / Q000494:pharmacology; D002454:Cell Differentiation / Q000187:drug effects / Q000502:physiology*; D002460:Cell Line; D002762:Cholecalciferol / Q000494:pharmacology*; D019295:Computational Biology; D016208:Databases, Factual; D011464:Epoprostenol / Q000031:analogs & derivatives / Q000494:pharmacology; D020869:Gene Expression Profiling; D006410:Hematopoiesis; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000378:metabolism; D008024:Ligands; D009000:Monocytes / Q000166:cytology* / Q000187:drug effects / Q000502:physiology; D047494:PPAR delta / Q000096:biosynthesis / Q000502:physiology*; D013844:Thiazoles / Q000494:pharmacology; D015854:Up-Regulation
D018952:Antigens, CD34; D000943:Antigens, Differentiation; C425931:GW 501516; D008024:Ligands; D047494:PPAR delta; D013844:Thiazoles; D002762:Cholecalciferol; D016718:Arachidonic Acid; C026678:carboprostacyclin; D011464:Epoprostenol